Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. 2009

Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
Medical University of Lublin, Department of Pathophysiology, Lublin, Poland. czuczwarsj@yahoo.com

BACKGROUND At least 20 - 30% of epileptic patients do not sufficiently respond to monotherapy. Some of them can benefit from drug combinations; hence, animal data may provide some useful novel clues for rational polytherapy. OBJECTIVE To review combinations of antiepileptic drugs, evaluated with the help of isobolographic analysis, in terms of their efficacy and adverse effects. METHODS A literature search, on the basis of experimental studies, with no time limit was carried out. CONCLUSIONS Preclinical data indicate that a synergy occurred for the combinations of valproate + phenytoin, valproate + ethosuximide, lamotrigine + valproate, gabapentin + valproate, gabapentin + carbamazepine, topiramate + carbamazepine, topiramate + valproate, topiramate + oxcarbazepine, levetiracetam + topiramate, levetiracetam + oxcarbazepine, oxcarbazepine + gabapentin, tiagabine + gabapentin and lamotrigine + topiramate. On the other hand, lamotrigine combined with carbamazepine or oxcarbazepine resulted in a clear-cut antagonism. Interestingly, a combination of oxcarbazepine + clonazepam produced variable responses, including synergy, additivity or antagonism, depending on the dose ratio of these drugs. In no case did pharmacokinetic factors contribute to the final analysis of the effects of drug combinations. Pharmacokinetic factors can contribute to the final effect of drug combinations,such as when stiripentol is added to valproate, or clobazam is added to valproate. It may be concluded that the rational treatment of drug-resistant epilepsy needs to consider the results of preclinical studies.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
January 2022, Pharmacological research,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
January 2017, Current pharmaceutical design,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
December 2014, Epileptic disorders : international epilepsy journal with videotape,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
January 2008, International review of neurobiology,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
August 1980, Medizinische Monatsschrift fur Pharmazeuten,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
November 2013, Clinical pharmacokinetics,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
March 2020, Epilepsy & behavior : E&B,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
May 2015, Seizure,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
July 2003, The Lancet. Neurology,
Stanislaw J Czuczwar, and Jacek Kaplanski, and Grazyna Swiderska-Dziewit, and Aleksandra Gergont, and Slawomir Kroczka, and Marek Kacinski
January 2006, Drug safety,
Copied contents to your clipboard!